Stanislaw Burzynski

Stanislaw Burzynski

N/A

Most Known for...

Movie Picture

Burzynski, the Movie 2010 (6.3)

Burzynski, the Movie is the story of a medical doctor and Ph.D biochemist named Dr. Stanislaw Burzynski who won the largest, and possibly the most convoluted and intriguing legal battle against the Food & Drug Administration in American history. His victorious battles with the United States government were centered around Dr. Burzynski's gene-targeted cancer medicines he discovered in the 1970's called Antineoplastons, which have currently completed Phase II FDA-supervised clinical trials in 2009 and could begin the final phase of FDA testing in 2011–barring the ability to raise the required $300 million to fund the final phase of FDA clinical trials.
Movie Picture

Burzynski: Cancer Is Serious Business, Part II 2013 (8.8)

In the compelling follow-up to the internationally award-winning documentary, "Burzynski: the Movie,", Part II explores the current status of Antineoplastons' clinical testing sanctioned by the United States Food & Drug Administration - and features a modern story of the struggling journeys of cancer patients being treated today at the Burzynski Clinic in Houston, Texas. Since the mapping of the Cancer Genome, Burzynski has pioneered an expansion of his therapy, which he calls, "Personalized Gene-Targeted Cancer Therapy", where each patient's Genomic Cancer Atlas is mapped and a treatment regimen is personally tailored for each individual patient - vs. the conveyor belt, "one-size-fits-all" approach that current oncology adheres to.
Movie Picture

Burzynski: The Cancer Cure Cover-Up 2016

The modern biographical story of Stanislaw Burzynski, MD, PhD who discovered an innovative patent-protected cancer therapy currently enrolled in FDA clinical trials. This story sheds light on the current regulatory and industry roadblocks preventing these life-saving medications from reaching the market as of 2016. The current story of Stanislaw Burzynski, MD, PhD who discovered an innovative cancer therapy now enrolled in FDA clinical trials, and the regulatory and industry roadblocks preventing these life-saving medications from reaching the market.